Inactive Instrument

C4X Discovery Holdings plc

Equities

C4XD

GB00BQQ2RV18

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 09:16:00 25/04/2024 pm IST			5-day change	1st Jan Change
12 ^GBX	+27.32%		-.--%	+33.33%

25/04	Norcros sells Johnson Tiles UK; Trifast trading well	AN
25/04	C4X Discovery Set for Friday Delisting from London Bourse's AIM	MT

C4X Discovery Holdings making "slight pivot" to anti-inflammatory treatments

April 28, 2023 at 12:33 pm IST

(via NewsDirect)

C4X Discovery Holdings PLC (AIM:C4XD) CEO Clive Dix speaks to Thomas Warner from Proactive after releasing half-year results for the six months ending 31 January 2023. Dix gives his highlights from the interim results before turning his focus to what he describes as a "slight pivot" to anti-inflammatory treatments.

C4X has a portfolio of anti-inflammatory targets, including a molecule for COPD, and four or five new anti-inflammatory targets in the pipeline, which will be revealed in due course.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Latest news about C4X Discovery Holdings plc

Norcros sells Johnson Tiles UK; Trifast trading well	26/04	AN
C4X Discovery Set for Friday Delisting from London Bourse's AIM	25/04	MT
C4X Discovery shareholders approve of taking firm private	15/04	AN
C4X Discovery seeks AIM delisting but half-year revenue skyrockets	27/03	AN
C4X Discovery Seeks to Delist From London's AIM Amid Financial Markets Downturn	27/03	MT
Earnings Flash (C4XD.L) C4X DISCOVERY HOLDINGS Posts Fiscal H1 Revenue GBP24.6M	27/03	MT
Earnings Flash (C4XD.L) C4X DISCOVERY HOLDINGS Reports Fiscal H1 EPS GBX7.06	27/03	MT
C4X Discovery Holdings plc Reports Earnings Results for the Half Year Ended January 31, 2024	27/03	CI
C4X Discovery Holdings plc Announces Stepping Down of Mario Polywka as Non-Executive Director	18/01	CI
Stocks down ahead of US Fed minutes	03/01	AN
Stocks down before Fed minutes and US PMI data	03/01	AN
AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals	03/01	AN
Stocks mixed pre-Fed minutes, amid Asia losses	03/01	AN
C4X receives USD11 million from AstraZeneca following NRF2 trials	03/01	AN
Stocks to open flat pre-Fed minutes, jobs data	03/01	AN
C4X Discovery Shares Rise on AstraZeneca Milestone Payment	03/01	DJ
C4X Discovery Receives $11 Million Milestone Payment from AstraZeneca	03/01	MT
C4X Discovery Holdings plc Receives Milestone Payment of $11 Million from AstraZeneca	03/01	CI
C4X Discovery shares topple 10% as loss widens on higher costs	14/12	AN
Earnings Flash (C4XD.L) C4X DISCOVERY HOLDINGS Posts FY23 Revenue GBP1.7M	14/12	MT
Earnings Flash (C4XD.L) C4X DISCOVERY HOLDINGS Reports FY23 Loss GBX-4.42	14/12	MT
C4X Discovery Holdings plc Reports Earnings Results for the Full Year Ended July 31, 2023	14/12	CI
Transcript : C4X Discovery Holdings plc, 2023 Earnings Call, Dec 14, 2023	14/12
C4X Discovery inks Indivior deal, Digitalbox expands	01/23/01	AN
FTSE 100 Index Down 0.4% at Close, Dragged by Miners, Oil Stocks	01/23/01	DJ

Chart C4X Discovery Holdings plc

Duration

Period

More charts

Company Profile

C4X Discovery Holdings plc is a drug discovery company. The Company has a portfolio ranging from early-stage target opportunities to late-stage drug discovery programs. The Company has three commercially partnered programs with one candidate in clinical development. Its portfolio focuses on treatments for immuno-inflammatory diseases. The Companyâs pipeline products include MALT-1 Inhibitor, a4B7 Integrin Inhibitor, IL-17A Inhibitor, NRF-2 Activator, and others. Its target identification platform (Taxonomy3) is used to analyze complex genetic datasets to identify and characterize drug target candidates. Taxonomy3 offers the potential for patient stratification in clinical trials, ensuring patient targeting and the potential for rescuing failed clinical trials or for drug repurposing. PatientSeek is its new platform that applies the mathematical approach of Taxonomy3 to stratify patients for treatments based on their genetics.

Sector

Biotechnology & Medical Research

Calendar

12/12/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+67.53%	6.39TCr
IQVIA HOLDINGS INC.	-0.77%	4.18TCr
LONZA GROUP AG	+45.66%	4.07TCr
CELLTRION, INC.	-10.72%	2.71TCr
ICON PUBLIC LIMITED COMPANY	+13.30%	2.65TCr
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	1.87TCr
BIO-TECHNE CORPORATION	+4.70%	1.27TCr
UNITED THERAPEUTICS CORPORATION	+24.10%	1.21TCr
MEDPACE HOLDINGS, INC.	+27.41%	1.21TCr

Other Biotechnology & Medical Research